Previous 10 | Next 10 |
Abiomed (NASDAQ: ABMD) is committed to improving patient outcomes by performing FDA studies and post-market surveillance, collecting real-world evidence and identifying and sharing best practices. Impella is the most studied mechanical circulatory support device in the history of the FDA ...
After A Shaky Start, the Indexes Continue their Upward Drive Many market commentators suggested that the indexes retreated from strong futures based on the negative chatter coming from the trade talks. I think this is just lazy assumptions. As I have asserted last week, I think ultimatel...
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is underpriced by 25% to 50% relative to historical averages in 3 val...
Shares of Abiomed (NASDAQ: ABMD) dropped about 11% as of 12:39 p.m. EST on Monday. The double-digit plunge is traceable to a pair of clinical studies that were presented over the weekend that raise new questions about the usefulness of the company's Impella heart pumps. Two research teams p...
Abiomed ( ABMD -9.4% ) slumps on increased volume in early trade in apparent response to a pair of studies that showed its Impella heart pump is associated with higher mortality risk, bleeding and stroke in patients undergoing angioplasty to re-open clogged arteries. The data were presen...
Investment Thesis The investment thesis of this article is that a most important reason for investing in any stock is its potential for portfolio wealth-building and that requires informed forecasts of its likely future price. Abiomed Inc. ( ABMD ) now scores better than all other Medical ...
To mark the five year anniversary of the study by Stretch, et al., on cost and outcomes trends for short-term mechanical circulatory support, Abiomed announces a comprehensive publication review of cost and comparative effectiveness of Impella in high-risk PCI and cardiogenic shock. The d...
SAN DIEGO, CA / ACCESSWIRE / November 12, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Abiomed, Inc. (NASDAQ:ABMD) shares. Investors, who purchased shares of Abiomed, Inc. (NASDAQ:ABMD) in January 2019 or earlier and continue to hold a...
Profitable investing is what we, hopefully, all strive to achieve. However, I love investing in companies that, while focused on returning capital to shareholders, are also beneficial to society. Abiomed (ABMD) could not be more successful at both. Not only is the company killing it on a perfo...
The following slide deck was published by Abiomed, Inc. in conjunction with their 2020 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...